Anti-cancer compound
US-9486444-B1 · Nov 8, 2016 · US
Substituted spirooxindoles
US9822128B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9822128-B1 |
| Application number | US-201715611771-A |
| Country | US |
| Kind code | B1 |
| Filing date | Jun 1, 2017 |
| Priority date | Jun 1, 2017 |
| Publication date | Nov 21, 2017 |
| Grant date | Nov 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The substituted spirooxindoles are MDM2-p53 inhibitors bearing a benzylidine (styryl) arm and have a complex fused ring system ideally suited for binding to the MDM2 protein, thereby interrupting its protein-protein interaction (PPI). Sixteen compounds, designated 4a-4p, were synthesized in a simple smooth method using an asymmetric 1,3-dipolar reaction as the key step. Testing showed that the compounds exhibit anti-cancer activity against various forms of cancer cells affecting humans.
First claim
Opening claim text (preview).
We claim: 1. A substituted spirooxindole for cancer treatment, comprising a compound having the formula: wherein R 1 and R 4 are independently hydrogen or chlorine; R 2 is hydrogen, chlorine, fluorine bromine, trifluoromethyl, methyl, or methoxy; R 3 is hydrogen, nitro (NO 2 ), fluorine, or bromine; and R 5 is hydrogen, chlorine, or bromine. 2. A substituted spirooxindole for cancer treatment, comprising a compound having the formula: wherein X is sulfur or oxygen. 3. A substituted spirooxindole for cancer treatment, comprising a compound having the formula:
Assignees
Inventors
Classifications
- C07D513/20Primary
Spiro-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9822128B1 cover?
- The substituted spirooxindoles are MDM2-p53 inhibitors bearing a benzylidine (styryl) arm and have a complex fused ring system ideally suited for binding to the MDM2 protein, thereby interrupting its protein-protein interaction (PPI). Sixteen compounds, designated 4a-4p, were synthesized in a simple smooth method using an asymmetric 1,3-dipolar reaction as the key step. Testing showed that the …
- Who is the assignee on this patent?
- Univ King Saud
- What technology area does this patent fall under?
- Primary CPC classification C07D513/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).